Premium
Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations
Author(s) -
Nakamura K,
Goto F,
Ray W A,
McAllister C B,
Jacqz E,
Wilkinson G R,
Branch R A
Publication year - 1985
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1985.194
Subject(s) - mephenytoin , debrisoquine , hydroxylation , pharmacology , pharmacogenetics , cyp2d6 , cytochrome p450 , medicine , chemistry , biology , genotype , genetics , enzyme , metabolism , biochemistry , gene
Interethnic differences in debrisoquin and mephenytoin hydroxylation have been compared between normal white (n = 183) and Japanese (n = 100) subjects with the 8‐hour urinary metaboUc ratio of debrisoquin and the urinary S/R enantiomeric ratio of mephenytoin to identify extensive (EM) and poor (PM) metabolizers. In white subjects the frequency of PMs was 8.7% and 2.7% for debrisoquin and mephenytoin, respectively. In contrast, in Japanese subjects no PMs of debrisoquin were identified, while the incidence of PMs of mephenytoin was 18%. These substantial differences (P < 0.001) in polymorphic distributions of oxidative drug metabolizing ability have implications for interethnic efficacy and toxicity of drugs and other xenobiotics that are metabolized by the involved cytochrome P‐450 isozymes. Clinical Pharmacology and Therapeutics (1985) 38 , 402–408; doi: 10.1038/clpt.1985.194